Review of 2012 Research
Think of this as a companion piece to yesterday's entry about the basic biology of breast cancer. This is an interview with Dr Eric Winer and Dr Shom Goal about recent research and directions as we move further into 2013. Frankly, nothing in this piece is brand new information, but it is a very nice summary and captures the many areas of interest.
This is from MedScape, and I give you the introduction and an example as the first topic is Hormone-Receptor Positive Breast Cancer and recent trials. Following this segment, I will post a link to read more:
Breast Cancer: Moving Into 2013
Shom Goel, MD; Eric P. Winer, MD
The landscape of effective breast cancer therapies has evolved tremendously in the last decade, and it is encouraging to note that several trial results presented in 2012 have continued to advance the field. The range of new data presented over the last year was broad, incorporating practice-changing findings across early stage and metastatic settings. In this article, we review what we believe were the groundbreaking data reported from clinical breast cancer research in 2012, and discuss their immediate implications for the care of patients with breast cancer.
HORMONE RECEPTOR-POSITIVE BREAST CANCER
Although hormone receptor (HR)-positive breast cancers expressing either the estrogen receptor (ER), progesterone receptor (PR), or both (ER/PR), comprise 70% of all breast cancers and remain the predominant cause of breast cancer mortality, there had been relatively few advances in the management of these tumors since the advent of aromatase inhibitors (AIs) approximately a decade ago.[1-3] In the past 18 months, however, a number of important trial results have altered standards of care for patients with HRpositive breast cancer in the adjuvant and metastatic settings.
The ATLAS Trial: A Role for Extended Adjuvant Therapy With Tamoxifen
First, the long-awaited results of ATLAS were reported at the 2012 San Antonio Breast Cancer Symposium (SABCS),4 ATLAS is an international phase 3 trial that randomly assigned women with early stage breast cancer to receive adjuvant tamoxifen therapy for either 5 years (standard of care) or 10 years. The study recruited almost 13,000 patients (almost 7000 of whom had confirmed HRpositive
disease) and employed a pragmatic design that facilitated long-term follow-up of this large cohort. Randomization typically occurred after patients had already received tamoxifen for at least 4 years.